The Asia Pacific human vaccine adjuvants market was valued at US$ 330.19 million in 2022 and is expected to reach US$ 1.00 billion by 2030; it is estimated to register a CAGR of 15.0% from 2022 to 2030.
According to the EFPIA, the Brazilian, Chinese, and Indian pharmaceutical industries grew by 11.7%, 6.7%, and 11.8% during the 2016-2021 period, respectively, compared to the top five European Union markets and the US market, which recorded an average market growth of 5.8% and 5.6%, respectively. Furthermore, as per the India Brand Equity Foundation (IBEF), India is a major and rising global pharmaceutical industry player. The country is the world's largest trader of generic medications, accounting for nearly 20% of the worldwide supply by volume. It supplies ~50% of the global vaccination demand. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units.
Based on official figures from the Indian government, the pharmaceutical sector in India is valued at nearly US$ 50 billion, of which over US$ 25 billion is derived from exports. India accounts for ~20% of the world's generic medicine exports. Further, Japan is one of the largest pharmaceutical markets in the world. According to the Ministry of Health, Labor and Welfare's (MHLW) Annual Pharmaceutical Production Statistics, the Japanese market for prescription and nonprescription pharmaceuticals in 2020 was US$ 107 billion.
As the industry continues to evolve and innovate, there is an increasing demand for adjuvants that can support the development of personalized vaccines, driving significant growth and investment in the Asia Pacific human vaccine adjuvants market. Thus, the growing pharmaceutical industry worldwide will likely create lucrative growth opportunities for the Asia Pacific human vaccine adjuvants market in the coming years.
An increase in the prevalence of infectious diseases is expected to fuel the demand for vaccinations. According to a report by the ICO/IARC Information Centre on HPV and Cancer in 2023, China has a population of 582.4 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. About 3.8% of women in China in the general population are estimated to harbor cervical HPV-16/18 infection at a given time, and 69.1% of invasive cervical cancers are attributed to HPVs 16 or 18. Thus, the rising number of patients and the increasing demand for vaccines for treatment are also expected to boost the Asia Pacific human vaccine adjuvants market growth.
Growing Pharmaceutical Industry Boosts Asia Pacific Human Vaccine Adjuvants Market
The expanding pharmaceutical industry is expected to positively influence the demand for adjuvants as they can improve the efficacy and safety of vaccines. The pharmaceutical industry's increasing focus on infectious diseases, cancer, and autoimmune disorders provides a platform for developing personalized vaccines and adjuvants targeted at these specific disease areas. This offers an opportunity for adjuvant manufacturers to develop specialized adjuvants to enhance the immune response to vaccines for these diseases.According to the EFPIA, the Brazilian, Chinese, and Indian pharmaceutical industries grew by 11.7%, 6.7%, and 11.8% during the 2016-2021 period, respectively, compared to the top five European Union markets and the US market, which recorded an average market growth of 5.8% and 5.6%, respectively. Furthermore, as per the India Brand Equity Foundation (IBEF), India is a major and rising global pharmaceutical industry player. The country is the world's largest trader of generic medications, accounting for nearly 20% of the worldwide supply by volume. It supplies ~50% of the global vaccination demand. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units.
Based on official figures from the Indian government, the pharmaceutical sector in India is valued at nearly US$ 50 billion, of which over US$ 25 billion is derived from exports. India accounts for ~20% of the world's generic medicine exports. Further, Japan is one of the largest pharmaceutical markets in the world. According to the Ministry of Health, Labor and Welfare's (MHLW) Annual Pharmaceutical Production Statistics, the Japanese market for prescription and nonprescription pharmaceuticals in 2020 was US$ 107 billion.
As the industry continues to evolve and innovate, there is an increasing demand for adjuvants that can support the development of personalized vaccines, driving significant growth and investment in the Asia Pacific human vaccine adjuvants market. Thus, the growing pharmaceutical industry worldwide will likely create lucrative growth opportunities for the Asia Pacific human vaccine adjuvants market in the coming years.
Asia Pacific Human Vaccine Adjuvants Market Overview
China has invested heavily in its healthcare and pharmaceutical industries, aiming to bolster domestic production, research, and development capabilities. This strategic focus has positioned the country as a key player in the Asia Pacific human vaccine adjuvants market. Additionally, China is among the most densely populated countries in the world; the current population is ~1.41 billion. According to the latest Global Burden of Disease (GBD) study published in October 2020, the population in the country is prone to various infectious, chronic, and acute diseases.An increase in the prevalence of infectious diseases is expected to fuel the demand for vaccinations. According to a report by the ICO/IARC Information Centre on HPV and Cancer in 2023, China has a population of 582.4 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. About 3.8% of women in China in the general population are estimated to harbor cervical HPV-16/18 infection at a given time, and 69.1% of invasive cervical cancers are attributed to HPVs 16 or 18. Thus, the rising number of patients and the increasing demand for vaccines for treatment are also expected to boost the Asia Pacific human vaccine adjuvants market growth.
Asia Pacific Human Vaccine Adjuvants Market Segmentation
The Asia Pacific human vaccine adjuvants market is categorized into type, application, end user, and country.- Based on type, the Asia Pacific human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.
- In terms of application, the Asia Pacific human vaccine adjuvants market is categorized into influenza, hepatitis, Human Papilloma Virus (HPV), and others. The influenza segment held the largest market share in 2022.
- By end user, the Asia Pacific human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.
- By country, the Asia Pacific human vaccine adjuvants market is segmented into Japan, China, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific human vaccine adjuvants market share in 2022.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Asia Pacific Human Vaccine Adjuvants Market - Key Market Dynamics
5. Human Vaccine Adjuvants Market - Asia Pacific Market Analysis
6. Asia Pacific Human Vaccine Adjuvants Market Analysis - by Type
7. Asia Pacific Human Vaccine Adjuvants Market Analysis - by Application
8. Asia Pacific Human Vaccine Adjuvants Market Analysis - by End User
9. Asia Pacific Human Vaccine Adjuvants Market - Country Analysis
10. Industry Landscape
11. Company Profiles
12. Appendix
Companies Mentioned
- Croda International Plc
- CSL Ltd
- Dynavax Technologies Corp
- Hawaii Biotech Inc
- Novartis AG
- Novavax Inc
- Phibro Animal Health Corp
- Seppic SA
- SPI Pharma Inc
